Cargando…

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer

BACKGROUND: An important component of the RAS signalling pathway, the RAS p21 oncogene, is frequently hyperactivated in breast cancer. Its expression in tumor tissue has been linked to poor clinical outcome. This study was designed to evaluate the clinical relevance of RAS p21 levels in peripheral b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banys-Paluchowski, Malgorzata, Fehm, Tanja, Janni, Wolfgang, Aktas, Bahriye, Fasching, Peter A., Kasimir-Bauer, Sabine, Milde-Langosch, Karin, Pantel, Klaus, Rack, Brigitte, Riethdorf, Sabine, Solomayer, Erich-Franz, Witzel, Isabell, Müller, Volkmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941516/ https://www.ncbi.nlm.nih.gov/pubmed/29739347 http://dx.doi.org/10.1186/s12885-018-4282-0

Ejemplares similares

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2017)

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
por: Müller, Volkmar, et al.
Publicado: (2012)

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Müller, Volkmar, et al.
Publicado: (2011)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

Circulating and Disseminated Tumor Cells in Breast Carcinoma: Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
por: Fehm, Tanja, et al.
Publicado: (2009)

Circulating and Disseminated Tumour Cells in Breast Carcinoma: Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression
por: Roth, Carina, et al.
Publicado: (2011)

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2009)

Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer
por: Aktas, Bahriye, et al.
Publicado: (2022)

Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
por: Fehm, Tanja N., et al.
Publicado: (2022)

Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer
por: Fehm, Tanja N., et al.
Publicado: (2023)

Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2023)

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
por: Müller, V., et al.
Publicado: (2021)

Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer
por: Müller, Volkmar, et al.
Publicado: (2022)

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
por: Müller, Volkmar, et al.
Publicado: (2023)

Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2016)

Liquid Biopsy in Breast Cancer
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2020)

Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer
por: Welslau, Manfred, et al.
Publicado: (2022)

Circulating microRNAs: promising breast cancer biomarkers - authors' response
por: Roth, Carina, et al.
Publicado: (2011)

Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
por: Roth, Carina, et al.
Publicado: (2010)

Evaluation of a novel ELISA for the tumor-associated antigen CA 72–4 in patients with ovarian cancer
por: Buderath, Paul, et al.
Publicado: (2016)

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2012)

Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies
por: Kolberg, Hans-Christian, et al.
Publicado: (2023)

Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
por: Lux, Michael P., et al.
Publicado: (2023)

Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer
por: Hartkopf, Andreas D., et al.
Publicado: (2023)

Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial
por: Banys, Malgorzata, et al.
Publicado: (2013)

Clinical Relevance of Loss of 11p15 in Primary and Metastatic Breast Cancer: Association with Loss of PRKCDBP Expression in Brain Metastases
por: Wikman, Harriet, et al.
Publicado: (2012)

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
por: Meng, Xiaodan, et al.
Publicado: (2016)

Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma
por: Oliveira-Ferrer, Leticia, et al.
Publicado: (2020)

Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2016)

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients
por: Riethdorf, Sabine, et al.
Publicado: (2009)

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients
por: Eichelser, Corinna, et al.
Publicado: (2014)

Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer?
por: Polasik, Arkadius, et al.
Publicado: (2017)

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment
por: Bredemeier, Maren, et al.
Publicado: (2016)

Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2020)

Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
por: Chebouti, Issam, et al.
Publicado: (2016)

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer
por: Witzel, Isabell, et al.
Publicado: (2014)

Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer
por: Legler, Karen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bke8ce73em3eeh8hum23iur1b4